Acrivon Therapeutics, Inc. Leases Disclosure
7. Leases
In December 2020, the Company entered into an operating lease agreement for laboratory and office space located at 480 Arsenal Way, Watertown, Massachusetts (the “Arsenal Way Lease”). The lease commenced in April 2021, with a term of seven years and an option to extend the term for an additional five years at then-market rental rates. The Company delivered a letter of credit of $0.3 million to the landlord, which was subsequently reduced to $0.2 million in August 2024 in accordance with the lease, which is included in restricted cash in the accompanying consolidated balance sheets. Under the terms of the lease, the base rent is $1.0 million, subject to a 3% annual rent increase, plus an allocation of operating expenses and taxes.
In August 2023, the Company entered into an operating lease agreement, denominated in Swedish Krona, for office and laboratory space located in Lund, Sweden. The term of the lease commenced in December 2023. The lease has an initial term of three years and will automatically renew for an additional term of three years unless the Company provides written notice of termination nine months prior to the termination date.
In July 2024, the Company entered into an operating lease agreement, denominated in Swedish Krona, for additional office and laboratory space adjacent to its existing leased space located in Lund, Sweden. The term of the lease commenced in September 2024. The lease has an initial term of three years and will automatically renew for an additional term of three years unless the Company provides written notice of termination nine months prior to the termination date.
The following table summarizes the presentation of the Company’s operating leases on its consolidated balance sheets as of December 31, 2025 and 2024 (in thousands):
Leases |
|
Balance sheet classification |
|
December 31, 2025 |
|
|
December 31, 2024 |
|
||
Assets: |
|
|
|
|
|
|
|
|
||
Operating lease assets |
|
Operating lease right-of-use assets |
|
$ |
2,527 |
|
|
$ |
3,554 |
|
Total lease assets |
|
|
|
$ |
2,527 |
|
|
$ |
3,554 |
|
Liabilities: |
|
|
|
|
|
|
|
|
||
Current: |
|
|
|
|
|
|
|
|
||
Operating lease liabilities |
|
Operating lease liability, current |
|
$ |
1,172 |
|
|
$ |
1,057 |
|
Noncurrent: |
|
|
|
|
|
|
|
|
||
Operating lease liabilities |
|
Operating lease liability, non-current |
|
|
1,537 |
|
|
|
2,588 |
|
Total lease liabilities |
|
|
|
$ |
2,709 |
|
|
$ |
3,645 |
|
The components of lease cost under ASC 842 included within research and development expenses and general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024 were as follows (in thousands):
|
|
For the Year Ended December 31, |
|
|||||
Lease cost |
|
2025 |
|
|
2024 |
|
||
Operating lease cost |
|
$ |
1,293 |
|
|
$ |
1,276 |
|
Variable lease cost |
|
|
608 |
|
|
|
645 |
|
Total lease cost |
|
$ |
1,901 |
|
|
$ |
1,921 |
|
As of December 31, 2025 and 2024, the weighted-average remaining lease term for operating leases was 2.3 years and 3.2 years, respectively, and the weighted-average discount rate was 8.17% and 8.26%, respectively. Cash paid for amounts included in the measurement of lease liabilities was $1.3 million and $1.4 million for the years ended December 31, 2025 and 2024, respectively.
Future minimum annual lease commitments under the Company’s non-cancelable operating leases as of December 31, 2025 were as follows (in thousands):
Year ended December 31, |
|
Amount |
|
|
2026 |
|
$ |
1,341 |
|
2027 |
|
|
1,210 |
|
2028 |
|
|
404 |
|
Total lease payments |
|
|
2,955 |
|
Less: interest |
|
|
(246 |
) |
Present value of operating lease liabilities |
|
$ |
2,709 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 19, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
| 2023 | Mar 28, 2024 | |
| 2022 | Mar 28, 2023 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.